AFMD | Affimed N.V. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.62 - 3.89
52 Week Range	2.2400 - 8.95
Beta	1.37
Implied Volatility	409.80%
IV Rank	28.66%
Day's Volume	82,796
Average Volume	188,256
Shares Outstanding	15,227,500
Market Cap	57,255,400
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-09-12

Valuation
Profitability
Growth
Health
P/E Ratio	-0.65
Forward P/E Ratio	N/A
EPS	-5.81
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	76
Country	Germany
Website	AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

AFMD's peers: ABEO, ABSI, ABUS, ADAP, ADVM, TCRR, PIRS, ADCT, AGEN, XFOR, TERN, DAWN, PDSB, INZY, LPTX, CRVS, APTO, EFTR, ELEV, MREO, HEPA, ATNM, CRBP, CRIS, GLMD, GRTS, INKT, MBIO, MNKD, MTNB, PGEN, RXRX, SLRX, TLSA

*Chart delayed

Analyzing fundamentals for AFMD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see AFMD Fundamentals page.

Watching at AFMD technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on AFMD Technicals page.